Wednesday, October 3, 2012

Takeda and Advinus initiate multi year drug discovery collaboration

Takeda and Advinus Therapeutics Ltd.  jointly announced today that they have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including Inflammation, CNS, and Metabolic diseases. In this collaboration, Advinus is responsible for leading the programs to create optimal IND ready compounds for pre-defined targets.



Under the terms of the agreement, Takeda will receive worldwide commercial rights to drug candidates emerging from this alliance. Advinus will receive guaranteed research funding of $36 million over the term of the collaboration, $9 million in milestones leading to candidate selection, and is eligible to receive future clinical and regulatory milestone payments of up to $45 million per product, plus royalties on product sales worldwide.